Cardiovascular Complications of Respiratory Disorders

Miguel Angel Martinez-Garcia is Section Head, Research Coordinator and Sleep Disordered Breathing Head of the Pulmonary Disorder Division of the University and Polytechnic La Fe Hospital in Valencia, Spain. Jean-Louis Pepin is Professor of Clinical Physiology at the University Grenoble-Alpes. He is Head of the Clinic of Physiology, Sleep and Exercise at Grenoble University Hospital, Director of the HP2 Laboratory, and vice-Dean of the Faculty of Medicine in charge or research and Scientific Director of clinical research at CHUGA. Mario Cazzola is an Honorary Professor of Respiratory Medicine at the University of Rome "Tor Vergata" and at the Sackler Institute of Pulmonary Pharmacology, GKT School of Biomedical Sciences.

Epidemiological aspects of cardiovascular and respiratory diseases; Common pathophysiological pathways of the autonomic nervous system; Murine models of cardiovascular damage in lung diseases; Cardiovascular disease in COPD; Management of patients with asthma or COPD and cardiovascular disease: risks versus benefits; Chronic asthma and the risk of cardiovascular disease; Cardiovascular implications in bronchiectasis; Cardiovascular complications of cystic fibrosis; Cardiovascular consequences of sleep disordered breathing: the role of CPAP treatment; The heart in obesity hypoventilation syndrome; Cardiovascular effects of innovative therapies in lung cancer; Cardiovascular implications of pulmonary hypertension due to chronic respiratory diseases; Cardiovascular mortality and morbidity in pulmonary embolism; The cardiovascular system in idiopathic pulmonary fibrosis; Cardiovascular consequences of community-acquired pneumonia and other pulmonary infections; Beta2-adrenoceptor modulation in COPD and its potential impact on cardiovascular comorbidities; Characterising the cardiovascular safety profile of inhaled muscarinic receptor antagonists; Impact of inhaled corticosteroids in patients with cardiovascular disease; Cardiovascular side-effects of common antibiotics; The cardiovascular effects of xanthines and selective PDE inhibitors: a risk-benefit analysis; Future challenges; Case reports